Expression of organic cation transporter SLC22A16 in human endometria

International Journal of Gynecological Pathology

Volumn 26, Issue 1, 2007, Pages 53-60

  Sato, Naoko ^a   Ito, Kiyoshi ^a   Onogawa, Toru ^a   Akahira, Jun Ichi ^a   Unno, Michiaki ^a   Abe, Takaaki ^b,c   Niikura, Hitoshi ^a   Yaegashi, Nobuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b University Graduate School of Medicine   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Adriamycin; Cancer; Endometrium; Organic cation transporter; Progesterone receptor

Indexed keywords

DOXORUBICIN; GESTAGEN; MESSENGER RNA; PROGESTERONE; PROTEIN; SLC22A16 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL; CELL PROLIFERATION; ENDOMETRIUM CARCINOMA; ENDOMETRIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; ORGANIC CATION TRANSPORT PROTEINS; PROGESTERONE; RNA, MESSENGER;

EID: 33845954640     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pgp.0000225845.67245.b3     Document Type: Article

References (28)

1. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. J Epidemiol Biostat 2001;6:48-88.
2. Carter SK. Adriamycin-A review. J Natl Cancer Inst 1975;55:1265-75.
3. Gigli M, Doglia SM, Millot JM, et al. Quantitative study of doxorubicin in living cell nuclei by microspectrofluorometry. Biochim Biophys Acta 1988;950:13-20.
4. Inui KI, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int 2000;58:944-58.
5. Fojo AT, Ueda K, Slamon DJ, et al. Cellular localization of the multidrug-resistance gene in human tumors and tissues. Proc Natl Acad USA Sci 1987;84:265-9.
6. Loo TM, Bartlett MC, Clarke DM. Simultaneous binding of two different drugs in the binding pocket of human multidrug resistance P-glycoprotein. J Biol Chem 2003;278:39706-10.
7. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47:381-889.
8. Ueda K, Cardarelli C, Gottesmant MM, et al. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicines,doxorubicin, and vinblastine. Proc Natl Acad USA Sci 1987;84:3004-8.
9. Hunter J, Hirst BH. The role of P-glycoprotein and related drug efflux system in limiting oral drug absorption. Adv Drug Deliv Rev 1997;25:129-57.
10. Skovsgaad T. Transport and binding of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumor cells. Biochem Pharmacol 1977;26:215-22.
11. Peterson C, Trouet A. Transport and strage of daunorubicin and doxorubicin in cultured fibroblasts. Cancer Res 1978;38:3649-4645.
12. Johnson BA, Cheang MS, Goldenberg GJ. Comparison of adriamycin uptake in chick embryo heart and liver cells and murine L5178-lymphoblasts in vitro. Role of drug uptake in cardiotoxicity. Cancer Res 1986;46:218-23.
13. Enomoto A, Wempe MF, Tsuchida H, et al. Molecular identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition. J Biol Chem 2002;277:36262-71.
14. Gong S, Lu X, Xu Y, et al. Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. Exp Hematol 2002;30:1162-9.
15. Okabe M, Unno M, Harigae H, et al. Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 2005;333:754-62.
16. Nishida M. The Ishikawa cells from birth to the present. Hum Cell 2002;15:104-17.
17. Kuramoto H. Studies of the growth and cytogenestic properties of human endometrial adenocarcinoma in culture and its development into an established line. Acta Obstet Gynaecol Jpn 1972;19:47-58.
18. Satoh T, Nishida M, Miyazaki Y, et al. Establish of cisplatin-resistant new human endometrial adenocarcinoma cell line. Sawano cells. Hum Cell 1995;8:67-72.
19. Ishiwata I, Ishiwata C, Soma M, et al. Establishment of human endometrial adenocarcinoma cell line containing estradiol-17 beta and progesterone receptors. Gynecol Oncol 1984;17:281-90.
20. FIGO Annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet 1989;28:189-93.
21. FIGO Changes in gynecological cancer staging by the International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 1990;162:610-1.
22. Akahira J, Suzuki T, Ito K, et al. Differential expression of progesterone receptor idoforms A and B in the normal ovary, and in benign, borderline, and malignant ovarian tumors. Jpn J Cancer Res 2000;93:807-15.
23. Abe T, Kakyo M, Tokui T, et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 1999;274:17159-63.
24. Mikkaichi T, Suzuki T, Onogawa T, et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad USA Sci 2004;101:3569-74.
25. Utsunomiya H, Suzuku T, Ito K, et al. The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma. Clin Endoclinology 2002;58:696-703.
26. Dai D, Litman ES, Schonteich E, et al. Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth. J Steroid Biochem Moi Biol 2003;87:123-31.
27. Markman M. Hormonal therapy of endometrial cancer. Eur J Cancer 2005;41:673-5.
28. Ayoub J, Audet-Lapointe P, Methot Y, et al. Efficancy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status. Gynecol Oncol 1988;31:327-37.